OBESITY AND IMMUNITY

Prevention of Obesity-Related Inflammation

Coordinatore	FUNDACION UNIVERSITARIA BALMES    more  Organization address address: SAGRADA FAMILIA 7 city: VIC (BARCELONA) postcode: 8500 contact info Titolo: Mr. Nome: Josep M. Cognome: Clotas Pau Email: send email Telefono: +3493 881 60 27 Fax: +34 93 889 10 63
Nazionalità Coordinatore	Spain [ES]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-4-3-IRG
Funding Scheme	MC-IRG
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-11-01   -   2012-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACION UNIVERSITARIA BALMES  Organization address address: SAGRADA FAMILIA 7 city: VIC (BARCELONA) postcode: 8500 contact info Titolo: Mr. Nome: Josep M. Cognome: Clotas Pau Email: send email Telefono: +3493 881 60 27 Fax: +34 93 889 10 63	ES (VIC (BARCELONA))	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'According to the World Health Organization (WHO), 1.6 billion adults are overweight and 300 million people are obese worldwide. One of the major consequences of these high rates is manifested by the increased prevalence of Type II Diabetes Mellitus (T2D). The search for novel therapies requires a better understanding of the T2D pathophysiology. In this regard, there is still a considerable lack of knowledge concerning the immunopathogenesis of T2D. We discovered a natural phytohormone -- abscisic acid (ABA) -- with significant glucose normalizing and immunomodulatory properties, which may prove instrumental in exploring the links between immunity and T2D. Our preliminary data suggest that ABA ameliorates glucose tolerance and white adipose tissue (WAT) inflammation by acting on peroxisome proliferator-activated receptor γ (PPAR γ). Our long-term goal is to characterize the mechanisms by which ABA ameliorates obesity-related inflammation. Specific aim 1 will test the hypothesis that ABA down-modulates monocyte chemoattractant protein-1 (MCP-1) production through a PPAR γ-mediated blockade of nuclear factor-κB (NF-κB). More specifically, we will dissect the mechanisms of transcriptional regulation of MCP-1 expression by ABA by: 1) Determining the influence of ABA treatment on the DNA-binding activity of NF-κB in macrophages; 2) Investigating whether ABA represses the expression of NF-κB subunits or induces IκBα expression under inflammatory conditions, 3) Assessing the physical interaction of ABA-activated PPAR γ and RelA and its role in inhibiting MCP-1 expression in macrophages; and 4) Determining if ABA suppresses obesity-induced MCP-1 expression by activating PPAR γ and inhibiting NF-κB. Specific Aim 2 will evaluate the differential ability of ABA’s enantiomers and isomers to bind and activate PPAR γ in vitro and determine whether macrophage PPAR γ is required for ABA’s induced improvement of insulin resistance during diet-induced obesity.'